Daniel Ebner
Group Head / PI and Member of congregation
The High Throughput Screening Facility is a major component of the Target Discovery Institute (or TDI) which is a new research centre initiated by the Nuffield Department of Medicine and the University of Oxford with a mandate to develop new target screening methodologies, investigate disease pathways as a means for identifying 'drug targets' and advance therapeutically relevant targets for drug development.
The aim of the high throughput screening facility at the TDI is to provide research scientists with access to a comprehensive, cost-effective facility capable of running high throughput cell based small compound and RNAi screens as well as biochemical small compound screens
Recent publications
-
Differential effects of HIF2α antagonist and HIF2α silencing in renal cancer and sensitivity to repurposed drugs
Journal article
Arnaiz E. et al, (2021), BMC Cancer, 21
-
The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers
Journal article
Lumley SF. et al, (2021), Clinical Infectious Diseases, 73, e699 - e709
-
Therapeutic targeting of SETD2-deficient cancer cells with the small-molecule compound RITA
Journal article
Lopez KA. et al, (2021)
-
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Working paper
Abani O. et al, (2021), The Lancet, 397, 2049 - 2059
-
Genome-wide CRISPR/Cas9-knockout in human induced Pluripotent Stem Cell (iPSC)-derived macrophages.
Journal article
Navarro-Guerrero E. et al, (2021), Sci Rep, 11